Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

Keith Flaherty; Adil Daud; Jeffrey S. Weber; Jeffrey Alan Sosman; Kevin Kim; Rene Gonzalez; Omid Hamid; Jeffrey R. Infante; Jonathan S. Cebon; Lynn Mara Schuchter; Georgina V. Long; Alain Patrick Algazi; Ragini Reiney Kudchadkar; Igor Puzanov; Donald P. Lawrence; Amy S. Kline; Elizabeth Ann Cunningham; Peng Sun; Kiran Patel; Richard Kefford

doi:10.1200/jco.2014.32.15_suppl.9010

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

Keith Flaherty, Adil Daud, Jeffrey S. Weber, Jeffrey Alan Sosman, Kevin Kim, Rene Gonzalez, Omid Hamid, Jeffrey R. Infante, Jonathan S. Cebon, Lynn Mara Schuchter, Georgina V. Long, Alain Patrick Algazi, Ragini Reiney Kudchadkar, Igor Puzanov, Donald P. Lawrence, Amy S. Kline, Elizabeth Ann Cunningham, Peng Sun, Kiran Patel, Richard Kefford

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	9010
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	32
Issue number	15 supplement
DOIs	https://doi.org/10.1200/jco.2014.32.15_suppl.9010
Publication status	Published - 20 May 2014
Externally published	Yes
Event	50th Annual Meeting of the American-Society-of-Clinical-Oncology - Chicago, United States Duration: 30 May 2014 → 3 Jun 2014

Access to Document

10.1200/jco.2014.32.15_suppl.9010

Cite this

Flaherty, K., Daud, A., Weber, J. S., Sosman, J. A., Kim, K., Gonzalez, R., Hamid, O., Infante, J. R., Cebon, J. S., Schuchter, L. M., Long, G. V., Algazi, A. P., Kudchadkar, R. R., Puzanov, I., Lawrence, D. P., Kline, A. S., Cunningham, E. A., Sun, P., Patel, K., & Kefford, R. (2014). Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). Journal of Clinical Oncology, 32(15 supplement), 9010. https://doi.org/10.1200/jco.2014.32.15_suppl.9010

@article{f06b2b00708543ce9f599ebd5962a295,

title = "Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).",

author = "Keith Flaherty and Adil Daud and Weber, {Jeffrey S.} and Sosman, {Jeffrey Alan} and Kevin Kim and Rene Gonzalez and Omid Hamid and Infante, {Jeffrey R.} and Cebon, {Jonathan S.} and Schuchter, {Lynn Mara} and Long, {Georgina V.} and Algazi, {Alain Patrick} and Kudchadkar, {Ragini Reiney} and Igor Puzanov and Lawrence, {Donald P.} and Kline, {Amy S.} and Cunningham, {Elizabeth Ann} and Peng Sun and Kiran Patel and Richard Kefford",

year = "2014",

month = may,

day = "20",

doi = "10.1200/jco.2014.32.15_suppl.9010",

language = "English",

volume = "32",

pages = "9010",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15 supplement",

note = "50th Annual Meeting of the American-Society-of-Clinical-Oncology ; Conference date: 30-05-2014 Through 03-06-2014",

}

Flaherty, K, Daud, A, Weber, JS, Sosman, JA, Kim, K, Gonzalez, R, Hamid, O, Infante, JR, Cebon, JS, Schuchter, LM, Long, GV, Algazi, AP, Kudchadkar, RR, Puzanov, I, Lawrence, DP, Kline, AS, Cunningham, EA, Sun, P, Patel, K & Kefford, R 2014, 'Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).', Journal of Clinical Oncology, vol. 32, no. 15 supplement, pp. 9010. https://doi.org/10.1200/jco.2014.32.15_suppl.9010

Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). / Flaherty, Keith; Daud, Adil; Weber, Jeffrey S. et al.
In: Journal of Clinical Oncology, Vol. 32, No. 15 supplement, 20.05.2014, p. 9010.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

AU - Flaherty, Keith

AU - Daud, Adil

AU - Weber, Jeffrey S.

AU - Sosman, Jeffrey Alan

AU - Kim, Kevin

AU - Gonzalez, Rene

AU - Hamid, Omid

AU - Infante, Jeffrey R.

AU - Cebon, Jonathan S.

AU - Schuchter, Lynn Mara

AU - Long, Georgina V.

AU - Algazi, Alain Patrick

AU - Kudchadkar, Ragini Reiney

AU - Puzanov, Igor

AU - Lawrence, Donald P.

AU - Kline, Amy S.

AU - Cunningham, Elizabeth Ann

AU - Sun, Peng

AU - Patel, Kiran

AU - Kefford, Richard

PY - 2014/5/20

Y1 - 2014/5/20

U2 - 10.1200/jco.2014.32.15_suppl.9010

DO - 10.1200/jco.2014.32.15_suppl.9010

M3 - Meeting abstract

SN - 0732-183X

VL - 32

SP - 9010

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15 supplement

T2 - 50th Annual Meeting of the American-Society-of-Clinical-Oncology

Y2 - 30 May 2014 through 3 June 2014

ER -

Flaherty K, Daud A, Weber JS, Sosman JA, Kim K, Gonzalez R et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). Journal of Clinical Oncology. 2014 May 20;32(15 supplement):9010. doi: 10.1200/jco.2014.32.15_suppl.9010